DAE HWA Pharmaceutical Co. Ltd (067080) - Total Assets
Based on the latest financial reports, DAE HWA Pharmaceutical Co. Ltd (067080) holds total assets worth ₩220.34 Billion KRW (≈ $149.32 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DAE HWA Pharmaceutical Co. Ltd - Total Assets Trend (2011–2025)
This chart illustrates how DAE HWA Pharmaceutical Co. Ltd's total assets have evolved over time, based on quarterly financial data. Also see DAE HWA Pharmaceutical Co. Ltd stock valuation for the company's overall valuation and market capitalisation.
DAE HWA Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
DAE HWA Pharmaceutical Co. Ltd's total assets of ₩220.34 Billion consist of 29.6% current assets and 70.4% non-current assets. Review DAE HWA Pharmaceutical Co. Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.6% |
| Accounts Receivable | ₩19.31 Billion | 9.2% |
| Inventory | ₩35.18 Billion | 16.7% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩29.61 Billion | 14.0% |
| Goodwill | ₩693.16 Million | 0.3% |
Asset Composition Trend (2011–2025)
This chart illustrates how DAE HWA Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See DAE HWA Pharmaceutical Co. Ltd stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DAE HWA Pharmaceutical Co. Ltd's current assets represent 29.6% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2025, down from 2.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 1.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 16.7% of total assets.
DAE HWA Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of DAE HWA Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Wanbangde Pharmaceutical Holding Group Co Ltd
SHE:002082
|
China | CN¥4.55 Billion |
DAE HWA Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.56 | 0.49 | 0.73 |
| Quick Ratio | 0.27 | 0.24 | 0.49 |
| Cash Ratio | 0.00 | 0.00 | 0.06 |
| Working Capital | ₩-53.61 Billion | ₩-62.15 Billion | ₩-22.50 Billion |
DAE HWA Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between DAE HWA Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.43 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.4% |
| Total Assets | ₩210.86 Billion |
| Market Capitalization | $138.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values DAE HWA Pharmaceutical Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: DAE HWA Pharmaceutical Co. Ltd's assets grew by 2.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
The table below shows the annual total assets of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩210.86 Billion ≈ $142.90 Million |
+2.42% |
| 2024-12-31 | ₩205.88 Billion ≈ $139.52 Million |
-6.06% |
| 2023-12-31 | ₩219.16 Billion ≈ $148.52 Million |
+10.10% |
| 2022-12-31 | ₩199.06 Billion ≈ $134.90 Million |
+12.22% |
| 2021-12-31 | ₩177.38 Billion ≈ $120.21 Million |
+1.33% |
| 2020-12-31 | ₩175.05 Billion ≈ $118.63 Million |
+5.36% |
| 2019-12-31 | ₩166.15 Billion ≈ $112.59 Million |
+2.52% |
| 2018-12-31 | ₩162.06 Billion ≈ $109.82 Million |
-2.07% |
| 2017-12-31 | ₩165.47 Billion ≈ $112.14 Million |
+7.59% |
| 2016-12-31 | ₩153.80 Billion ≈ $104.23 Million |
+23.43% |
| 2015-12-31 | ₩124.61 Billion ≈ $84.45 Million |
+0.43% |
| 2014-12-31 | ₩124.07 Billion ≈ $84.08 Million |
+1.81% |
| 2013-12-31 | ₩121.87 Billion ≈ $82.59 Million |
-6.39% |
| 2012-12-31 | ₩130.19 Billion ≈ $88.23 Million |
-3.98% |
| 2011-12-31 | ₩135.58 Billion ≈ $91.88 Million |
-- |
About DAE HWA Pharmaceutical Co. Ltd
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthriti… Read more